Explore the words cloud of the ENDOSCAPE project. It provides you a very rough idea of what is the project "ENDOSCAPE" about.
The following table provides information about the project.
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
|Coordinator Country||Germany [DE]|
|Total cost||6˙850˙643 €|
|EC max contribution||6˙850˙643 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2019-01-01 to 2022-12-31|
Take a look of project's partnership.
|1||CHARITE - UNIVERSITAETSMEDIZIN BERLIN||DE (BERLIN)||coordinator||1˙381˙303.00|
|2||SAPREME TECHNOLOGIES BV||NL (BILTHOVEN)||participant||799˙160.00|
|3||MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV||DE (MUENCHEN)||participant||671˙878.00|
|4||VIB||BE (ZWIJNAARDE - GENT)||participant||584˙087.00|
|5||FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.||DE (MUNCHEN)||participant||540˙476.00|
|6||UNIVERSITA DEGLI STUDI DI FERRARA||IT (FERRARA)||participant||488˙750.00|
|7||EXTRASYNTHESE SAS||FR (GENAY)||participant||472˙500.00|
|8||UNIVERSIDAD DE SANTIAGO DE COMPOSTELA||ES (SANTIAGO DE COMPOSTELA)||participant||444˙237.00|
|9||FREIE UNIVERSITAET BERLIN||DE (BERLIN)||participant||429˙000.00|
|10||UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA||IT (ROMA)||participant||407˙500.00|
|11||TP21 GMBH||DE (BERLIN)||participant||370˙000.00|
|12||UNIVERSITAT BASEL||CH (BASEL)||participant||261˙750.00|
Gene therapy is one of the most promising treatment options for future advanced therapies in a broad range of diseases. Successful gene delivery requires the recognition of target cells as well as cytosolic and nucleosolic uptake of the gene. Currently, non-viral based gene delivery such as transfection reagents are only suitable for in vitro applications, and clinical gene therapeutics delivery is accomplished via viral vectors, which still has major safety concerns as well as complex and costly manufacturing procedures, preventing future implementation for the treatment of diseases with large patients groups.
In the last 15 years, a class of secondary plant metabolites has been discovered that selectively mediates endosomal escape and cytoplasmic delivery of macromolecules specifically at low endosomal pH, thereby inducing a 40-fold enhanced gene delivery efficacy in vivo. However, endosomal escape enhancers and gene therapeutic product must be applied as two components, thus complicating therapeutic approval and clinical applicability.
The ENDOSCAPE technology platform will develop and collect proof of concept for a non-viral gene delivery technology where endosomal escape enhancers, gene therapeutic product and targeting ligand are all bound to one molecular scaffold. Proof of concept of the ENDOSCAPE technology has a major impact on the therapeutic opportunities for current and future macromolecule drugs for a broad range of diseases and large patient groups.
All this induces new biotech-based businesses, new research projects and creates new technology platforms for development of new macromolecule therapeutics for a broad range of disease indications. The non-viral based ENDOSCAPE technology will enhance therapeutic efficacy with lower therapeutic dose thereby reducing costs of healthcare, improving the health of patients worldwide, and strengthening the competitive landscape of the EU in the worldwide quest for such an advanced technology.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDOSCAPE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ENDOSCAPE" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More
Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired PneumoniaRead More